```
### Status: Path 1 of [Dialog Information Services via Modem]

### Status: Initializing TCP/IP using (UseTelnetProto 1 ServiceID pto-dialog)
Trying 31060000009999...Open

DIALOG INFORMATION SERVICES
PLEASE LOGON:
 ******** HHHHHHHH SSSSSSSS?
### Status: Signing onto Dialog
 ********
ENTER PASSWORD:
 ******** HHHHHHHH SSSSSSSS? ********
Password incorrect
### Status: Incorrect Account Password.

### Status: Incorrect Account Password.

### Status: Path 1 of [Dialog Information Services via Modem]

### Status: Initializing TCP/IP using (UseTelnetProto 1 ServiceID pto-dialog)
Trying 31060000009999...Open

DIALOG INFORMATION SERVICES
PLEASE LOGON:
 ******** HHHHHHHH SSSSSSSS?
### Status: Signing onto Dialog
 ********
ENTER PASSWORD:
 ******** HHHHHHHH SSSSSSSS? ********
Password incorrect
### Status: Incorrect Account Password.

### Status: Incorrect Account Password.

### Status: Path 1 of [Dialog Information Services via Modem]

### Status: Initializing TCP/IP using (UseTelnetProto 1 ServiceID pto-dialog)
Trying 31060000009999...Open

DIALOG INFORMATION SERVICES
PLEASE LOGON:
 ******** HHHHHHHH SSSSSSSS?
### Status: Signing onto Dialog
 ********
ENTER PASSWORD:
 ******** HHHHHHHH SSSSSSSS? ********
Welcome to DIALOG
### Status: Connected


Dialog level 02.05.06D

Last logoff:  04jun02 16:15:16
Logon file001 05jun02 14:02:11
           *** ANNOUNCEMENT ***
                    ***
--Important Notice for Japanese KMKNET Users
KMKNET will be terminated on 5/31/02. Please
switch to DLGNET. Please refer to the G-Search
home page at http://www.g-search.or.jp
for more information.
                    ***
--SourceOne patents are now delivered to your
email inbox as PDF replacing TIFF delivery.
See HELP SOURCE1 for more information.
```

```
                    ***
--Important news for public and academic
libraries.  See HELP LIBRARY for more information.
                    ***
--Important Notice to Freelance Authors--
See HELP FREELANCE for more information
                    ***
For information about the access to file 43 please see Help News43.
***
NEW FILES RELEASED
***AGROProjects (File 235)
***TRADEMARKSCAN-Japan (File 669)
                    ***
UPDATING RESUMED
***Delphes European Business (File 481)
                    ***
RELOADED
***CLAIMS/US PATENTS (Files 340, 341, 942)
***Kompass Western Europe (590)
***D&B - Dun's Market Identifiers  (516)

REMOVED
***Baton Rouge Advocate (File 382)
***Washington Post (File 146)
***Books in Print (File 470)
***Court Filings (File 793)
***Microcomputer Software Guide Online (File 278)
***Publishers, Distributors & Wholesalers of the U.S. (File 450)
***State Tax Today (File 791)
***Tax Notes Today (File 790)
***Worldwide Tax Daily (File 792)
***New document supplier***
IMED has been changed to INFOTRIE (see HELP OINFOTRI)


>>>Get immediate news with Dialog's First Release
   news service.  First Release updates major newswire
   databases within 15 minutes of transmission over the
   wire.  First Release provides full Dialog searchability
   and full-text features.  To search First Release files in
   OneSearch simply BEGIN FIRST for coverage from Dialog's
   broad spectrum of news wires.

     >>> Enter BEGIN HOMEBASE for Dialog Announcements <<<
     >>>    of new databases, price changes, etc.      <<<
                    ****
KWIC is set to 50.
HILIGHT set on as '*'

File   1:ERIC  1966-2002/May 10
       (c) format only 2002 The Dialog Corporation

      Set  Items  Description
      ---  -----  -----------
Cost is in DialUnits
?b 155, 5, 73
       05jun02 14:02:22 User259876 Session D354.1
            $0.32    0.093 DialUnits File1
     $0.32  Estimated cost File1
     $0.04  TELNET
     $0.36  Estimated cost this search
     $0.36  Estimated total session cost   0.093 DialUnits


SYSTEM:OS  - DIALOG OneSearch
  File 155:MEDLINE(R)  1966-2002/May W4
```

***File 155: Daily alerts now available. This file has** been reloaded. Accession numbers have changed.
File 5:Biosis Previews(R) 1969-2002/May W4
(c) 2002 BIOSIS
File 73:EMBASE 1974-2002/May W4
(c) 2002 Elsevier Science B.V.
***File 73: For information about Explode feature please** see Help News73.

Set	Items	Description
?s (polynucleotide or RNA or DNA) (w) (ligand)		
	10087	POLYNUCLEOTIDE
	931438	RNA
	1760674	DNA
	232331	LIGAND
S1	718	(POLYNUCLEOTIDE OR RNA OR DNA) (W) (LIGAND)
?s s1 same (antivirus or antiviral)		
>>>Term "SAME" in invalid position		
?s s1 (s) (antivirus or antiviral)		
	718	S1
	16001	ANTIVIRUS
	118410	ANTIVIRAL
S2	3	S1 (S) (ANTIVIRUS OR ANTIVIRAL)
?rd		
...completed examining records		
S3	2	RD (unique items)

?t s3/3,k/all

3/3,K/1 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

12508099 BIOSIS NO.: 200000261601
In vitro selection of novel RNA ligands that bind human cytomegalovirus and block viral infection.
AUTHOR: Wang Jun; Jiang Hong; Liu Fenyong(a)
AUTHOR ADDRESS: (a) Program in Infectious Diseases and Immunity, School of Public Health, University of California, 140 Warren Hall, Berkeley, CA, 94720**USA
JOURNAL: RNA (New York) 6 (4):p571-583 April, 2000
MEDIUM: print.
ISSN: 1355-8382
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

QP 623.R52

DESCRIPTORS:
CHEMICALS & BIOCHEMICALS: ...*RNA* *ligand*, *antiviral*-drug, pharmacokinetics...

...*RNA* *ligand*, *antiviral*-drug, pharmacokinetics

3/3,K/2 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

02915560 BIOSIS NO.: 000069023677
HUMAN LEUKOCYTE INTERFERON RELATIONSHIP BETWEEN MOLECULAR STRUCTURE AND SPECIES SPECIFICITY
AUTHOR: THANG M N; THANG D C; CHELBI-ALIX M K; ROBERT-GALLIOT B; COMMOY-CHEVALIER M J; CHANY G
AUTHOR ADDRESS: INST. BIOL. PHYS.-CHIM., 13 RUE PIERRE ET MARIE CURIE, 75005 PARIS, FR.

JOURNAL: PROC NATL ACAD U S A 76 (8). 1979. 3717-3721 1979
FULL JOURNAL NAME: Proceedings of the National Academy of Sciences of the United States of America
CODEN: PNASA
RECORD TYPE: Abstract
LANGUAGE: ENGLISH

...ABSTRACT: of subspecies by polynucleotide-agarose affinity chromatography; 30-40% of the molecular species have the polynucleotide-binding property and 60-70% lack affinity for the *polynucleotide* *ligand*. When analyzed on sodium dodecyl sulfate-polyacrylamide gel electrophoresis, the former class of interferon has a slower mobility corresponding to the migration of a polypeptide...
...cells. The polypeptide domain responsible for species specificity may be closely related to the polynucleotide binding area. The modified interferon molecule, however, still conserves its *antiviral* activity. The simplicity and the high capacity of polynucleotide-agarose chromatography make this a powerful technique for the purification of interferon. The easy separation of...
?ds

Set	Items	Description
S1	718	(POLYNUCLEOTIDE OR RNA OR DNA) (W) (LIGAND)
S2	3	S1 (S) (ANTIVIRUS OR ANTIVIRAL)
S3	2	RD (unique items)

```
?s s1 and (virus (w) (capsid or envelope))
          718  S1
      1114156  VIRUS
        29643  CAPSID
        78588  ENVELOPE
        13681  VIRUS(W)(CAPSID OR ENVELOPE)
   S4       0  S1 AND (VIRUS (W) (CAPSID OR ENVELOPE))
?s s1 and (gB or gH or gL)
          718  S1
         7725  GB
        60568  GH
         6341  GL
   S5       4  S1 AND (GB OR GH OR GL)
?rd
...completed examining records
   S6       2  RD (unique items)
?t s6/3,k/all
```

6/3,K/1 (Item 1 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

06862842 91170880 PMID: 1706405
Secretion of insulin-like growth factor-I (IGF-I) and IGF-binding proteins from bovine mammary tissue in vitro.
Campbell P G; Skaar T C; Vega J R; Baumrucker C R
Department of Dairy and Animal Science, Pennsylvania State University, University Park 16802.
Journal of endocrinology (ENGLAND) Feb 1991, 128 (2) p219-28, ISSN 0022-0795 Journal Code: 0375363
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

... animals respectively. Concentrations of IGFBPs in conditioned media from explants were similar for both physiological states at 2529 pmol 125I-labelled IGF-I bound/micrograms *DNA*. *Ligand* /Western blotting procedures identified four IGFBPs of 29, 33, 37 and 44 kDa for acini cultures and five IGFBPs of 28, 31, 36, 44 and...

... used as the ligand only bovine IGF-II (ED50 of 0.2 pmol) inhibited binding. The addition of prolactin, insulin and cortisol, with or without *GH* , did not affect secretion of either IGF-I or IGFBP. This report describes the ability of normal mammary tissue to synthesize and secrete IGF-I...

6/3,K/2 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2002 Elsevier Science B.V. All rts. reserv.

11575841 EMBASE No: 2002147380
Induced formation of a DNA bulge structure by a molecular wedge ligand - Postactivated neocarzinostatin chromophore
Gao X.; Stassinopoulos A.; Ji J.; Kwon Y.; Bare S.; Goldberg I.H.
X. Gao, Department of Chemistry, University of Houston, 4800 Calhoun Street, Houston, TX 77204-5003 United States
AUTHOR EMAIL: xgao@uh.edu
Biochemistry (BIOCHEMISTRY) (United States) 23 APR 2002, 41/16 (5131-5143)
CODEN: BICHA ISSN: 0006-2960
DOCUMENT TYPE: Journal ; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 30

...antitumor molecule. A thorough understanding of these results will provide the molecular basis for the binding and DNA chain cleavage properties of NCS-chrom. NCSi-*gb* is one of the postactivated mimics of NCS-chrom which is formed under thiol-free conditions and is able to bind to DNA. This report describes the structure refinement of the NCSi-*gb* -bulge-DNA complex [Stassinopoulos, A., Jie, J., Gao, X., and Goldberg, I. H. (1996) Science 272, 1943-1946] and the NMR characterization of the free bulge-DNA and free NCSi-*gb*. These results reveal that the formation of the complex involves conformational changes in both the DNA and the ligand molecule. Of mechanistic importance for the...

...the presence of bulge-DNA sequences, due to the promotion of the intramolecular radical quenching of the activated NCS-chrom. Interestingly, the binding of NCSi-*gb* promotes the formation of a bulge binding pocket; this was not found in the unbound DNA. NCS-chrom is unique among the enediyne antibiotics in...

...mechanisms of activation to form two different DNA binding and cleaving species. The two corresponding DNA complexes are compared. One, the bulge-DNA binder NCSi-*gb*, involves the major groove, and the second, the duplex binder NCSi-glu which is generated by glutathione-induced activation, involves the minor groove. Since the...
DRUG DESCRIPTORS:
**DNA*; **ligand*; *zinostatin chromophore
?ds

Set	Items	Description
S1	718	(POLYNUCLEOTIDE OR RNA OR DNA) (W) (LIGAND)
S2	3	S1 (S) (ANTIVIRUS OR ANTIVIRAL)
S3	2	RD (unique items)
S4	0	S1 AND (VIRUS (W) (CAPSID OR ENVELOPE))
S5	4	S1 AND (GB OR GH OR GL)
S6	2	RD (unique items)

```
?s s1 and (viral (w) infection)
            718  S1
         563287  VIRAL
        1583416  INFECTION
          27890  VIRAL(W)INFECTION
      S7      2  S1 AND (VIRAL (W) INFECTION)
?rd
...completed examining records
```

S8 1 RD (unique items)
?t s8/3,k/all

8/3,K/1 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

12508099 BIOSIS NO.: 200000261601
In vitro selection of novel RNA ligands that bind human cytomegalovirus and block *viral* *infection*.
AUTHOR: Wang Jun; Jiang Hong; Liu Fenyong(a)
AUTHOR ADDRESS: (a)Program in Infectious Diseases and Immunity, School of Public Health, University of California, 140 Warren Hall, Berkeley, CA, 94720**USA
JOURNAL: RNA (New York) 6 (4):p571-583 April, 2000
MEDIUM: print.
ISSN: 1355-8382
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

In vitro selection of novel RNA ligands that bind human cytomegalovirus and block *viral* *infection*.

...ABSTRACT: sequences after 16 cycles of selection and amplification. The two ligands (L13 and L19) characterized exhibited high HCMV-binding affinity in vitro and effectively inhibited *viral* *infection* in tissue culture. Their antiviral activity was also specific as they only reacted with two different strains of HCMV but not with the related herpes...

...the feasibility of using these RNA ligands as a research tool to identify viral proteins required for infectivity and as an antiviral agent to block *viral* *infection*.
DESCRIPTORS:
CHEMICALS & BIOCHEMICALS: ...*RNA* *ligand*, antiviral-drug, pharmacokinetics...

...*RNA* *ligand*, antiviral-drug, pharmacokinetics
?ds

Set	Items	Description
S1	718	(POLYNUCLEOTIDE OR RNA OR DNA) (W) (LIGAND)
S2	3	S1 (S) (ANTIVIRUS OR ANTIVIRAL)
S3	2	RD (unique items)
S4	0	S1 AND (VIRUS (W) (CAPSID OR ENVELOPE))
S5	4	S1 AND (GB OR GH OR GL)
S6	2	RD (unique items)
S7	2	S1 AND (VIRAL (W) INFECTION)
S8	1	RD (unique items)

?s s1 and (antiviral or antivirus)
718 S1
118410 ANTIVIRAL
16001 ANTIVIRUS
S9 10 S1 AND (ANTIVIRAL OR ANTIVIRUS)
?rd
...completed examining records
S10 7 RD (unique items)
?t s10/3,k/all

10/3,K/1 (Item 1 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

09693264 98118468 PMID: 9457241
Modeling *RNA*-*ligand* interactions: the Rev-binding element RNA-aminoglycoside complex.

Leclerc F; Cedergren R
Departement de Biochimie, Universite de Montreal, Quebec, Canada.
Journal of medicinal chemistry (UNITED STATES) Jan 15 1998, 41 (2) p175-82, ISSN 0022-2623 Journal Code: 9716531
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

Modeling *RNA*-*ligand* interactions: the Rev-binding element RNA-aminoglycoside complex.
Descriptors: Antibiotics, Aminoglycoside--metabolism--ME; **Antiviral* Agents--metabolism--ME; *Gene Products, rev--metabolism--ME; *RNA, Viral --metabolism--ME
Chemical Name: Antibiotics, Aminoglycoside; *Antiviral* Agents; Gene Products, rev; Ligands; Macromolecular Systems; RNA, Viral

10/3,K/2 (Item 2 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

09323096 97234941 PMID: 9102100
Conjugates of oligodeoxyribonucleotides with lexitropsins, forming a *DNA*-*ligand* complex with a 1:2 ratio]
Kon''iugaty oligodezoksiribonukleotidov s leksitropsinami, obrazuiushchie kompleksy DNK-ligand sostava 1:2.
Siniakov A N; Riabinin V A; Gorbunov Iu A; Lokhov S G; Baklanov M M; Babkina I N; Sandakhchiev L S
Doklady Akademii nauk / Rossiiskaia akademii nauk (RUSSIA) Jan 1997, 352 (2) p262-4, ISSN 0869-5652 Journal Code: 9301140
Document type: Journal Article
Languages: RUSSIAN
Main Citation Owner: NLM
Record type: Completed

Conjugates of oligodeoxyribonucleotides with lexitropsins, forming a *DNA*-*ligand* complex with a 1:2 ratio]
Descriptors: *Antiviral* Agents--chemistry--CH; *DNA--chemistry--CH; *Netropsin--analogs and derivatives--AA
Chemical Name: *Antiviral* Agents; lexitropsin; Netropsin; DNA

10/3,K/3 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

12508099 BIOSIS NO.: 200000261601
In vitro selection of novel RNA ligands that bind human cytomegalovirus and block viral infection.
AUTHOR: Wang Jun; Jiang Hong; Liu Fenyong(a)
AUTHOR ADDRESS: (a)Program in Infectious Diseases and Immunity, School of Public Health, University of California, 140 Warren Hall, Berkeley, CA, 94720**USA
JOURNAL: RNA (New York) 6 (4):p571-583 April, 2000
MEDIUM: print.
ISSN: 1355-8382
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

...ABSTRACT: and amplification. The two ligands (L13 and L19) characterized exhibited high HCMV-binding affinity in vitro and effectively inhibited viral infection in tissue culture. Their *antiviral* activity was also specific as they only reacted with two different strains of HCMV but not with the related herpes simplex virus 1 and human...

...procedure. Our study onstrates the feasibility of u g these RNA ligands as a research tool to identify viral proteins required for infectivity and as an *antiviral* agent to block viral infection.
DESCRIPTORS:
CHEMICALS & BIOCHEMICALS: ...*RNA* *ligand*, *antiviral*-drug, pharmacokinetics...

...*RNA* *ligand*, *antiviral*-drug, pharmacokinetics

10/3,K/4 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

10430336 BIOSIS NO.: 199699051481
Inhibitory *RNA* *ligand* to reserve transcriptase from feline immunodeficiency virus.
AUTHOR: Chen Hang; McBroom Douglas G; Zhu Ya-Qi; Gold Larry; North Thomas W (a)
AUTHOR ADDRESS: (a)Div. Biol. Sci., Univ. Montana, Missoula, MT 59812**USA
JOURNAL: Biochemistry 35 (21):p6923-6930 1996
ISSN: 0006-2960
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

Inhibitory *RNA* *ligand* to reserve transcriptase from feline immunodeficiency virus.
MISCELLANEOUS TERMS: *ANTIVIRAL*;

10/3,K/5 (Item 3 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

02915560 BIOSIS NO.: 000069023677
HUMAN LEUKOCYTE INTERFERON RELATIONSHIP BETWEEN MOLECULAR STRUCTURE AND SPECIES SPECIFICITY
AUTHOR: THANG M N; THANG D C; CHELBI-ALIX M K; ROBERT-GALLIOT B; COMMOY-CHEVALIER M J; CHANY G
AUTHOR ADDRESS: INST. BIOL. PHYS.-CHIM., 13 RUE PIERRE ET MARIE CURIE, 75005 PARIS,.FR.
JOURNAL: PROC NATL ACAD SCI U S A 76 (8). 1979. 3717-3721. 1979
FULL JOURNAL NAME: Proceedings of the National Academy of Sciences of the United States of America
CODEN: PNASA
RECORD TYPE: Abstract
LANGUAGE: ENGLISH

...ABSTRACT: of subspecies by polynucleotide-agarose affinity chromatography; 30-40% of the molecular species have the polynucleotide-binding property and 60-70% lack affinity for the *polynucleotide* *ligand*. When analyzed on sodium dodecyl sulfate-polyacrylamide gel electrophoresis, the former class of interferon has a slower mobility corresponding to the migration of a polypeptide...
...cells. The polypeptide domain responsible for species specificity may be closely related to the polynucleotide binding area. The modified interferon molecule, however, still conserves its *antiviral* activity. The simplicity and the high capacity of polynucleotide-agarose chromatography make this a powerful technique for the purification of interferon. The easy separation of...

10/3,K/6 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE

(c) 2002 Elsevier Scienc .V. All rts. reserv.

11237064 EMBASE No: 2001251611
Anti-HIV and cytotoxic activities of Ru(II)/Ru(III) polypyridyl complexes containing 2,6-(2prime-benzimidazolyl)-pyridine/chalcone as co-ligand
Mishra L.; Sinha R.; Itokawa H.; Bastow K.F.; Tachibana Y.; Nakanishi Y.; Kilgore N.; Lee K.-H.
L. Mishra, Department of Chemistry, Banaras Hindu University, Gaithersburg India
AUTHOR EMAIL: khlee@email.unc.edu
Bioorganic and Medicinal Chemistry (BIOORG. MED. CHEM.) (United Kingdom) 2001, 9/7 (1667-1671)
CODEN: BMECE ISSN: 0968-0896
PUBLISHER ITEM IDENTIFIER: S0968089601000748
DOCUMENT TYPE: Journal ; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 25

DRUG DESCRIPTORS:
DNA; *ligand*; chalcone; chalcone derivative--pharmacology--pd; chalcone derivative--drug toxicity--to; chalcone derivative--drug development--dv; chalcone derivative--drug comparison--cm; zidovudine--pharmacology--pd; zidovudine--drug...
MEDICAL DESCRIPTORS:
*cytotoxicity; **antiviral* activity; *Human immunodeficiency virus 1; * antineoplastic activity

10/3,K/7 (Item 2 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2002 Elsevier Science B.V. All rts. reserv.

05648316 EMBASE No: 1994048156
In vitro evolution of functional nucleic acids: High-affinity RNA ligands of HIV-1 proteins
Tuerk C.; MacDougal-Waugh S.
Biological/Envtl. Sciences Dept., Lappin Hall, Morehead State University,Morehead, KY 40351 United States
Gene (GENE) (Netherlands) 1993, 137/1 (33-39)
CODEN: GENED ISSN: 0378-1119
DOCUMENT TYPE: Journal; Conference Paper
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

QH442.G43

DRUG DESCRIPTORS:
**antivirus* agent--drug development--dv; *ligand; *nucleic acid; *rna; * virus protein
DRUG TERMS (UNCONTROLLED): *rna* *ligand*
?ds

Set	Items	Description
S1	718	(POLYNUCLEOTIDE OR RNA OR DNA) (W) (LIGAND)
S2	3	S1 (S) (ANTIVIRUS OR ANTIVIRAL)
S3	2	RD (unique items)
S4	0	S1 AND (VIRUS (W) (CAPSID OR ENVELOPE))
S5	4	S1 AND (GB OR GH OR GL)
S6	2	RD (unique items)
S7	2	S1 AND (VIRAL (W) INFECTION)
S8	1	RD (unique items)
S9	10	S1 AND (ANTIVIRAL OR ANTIVIRUS)
S10	7	RD (unique items)

?s s1 and (treatment or therapy)

	718	S1
	3813291	TREATMENT
	4408917	THERAPY
S11	74	S1 AND (TREATMENT OR THERAPY)

?s s11 and review

```
            74  S11
       1243606  REVIEW
   S12       6  S11 AND REVIEW
?rd
...completed examining records
   S13       4  RD (unique items)
?t s13/3,k/all
```

13/3,K/1 (Item 1 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

08335110 95094782 PMID: 8001543
An evaluation of receptor-mediated gene transfer using synthetic *DNA*-*ligand* complexes.
Perales J C; Ferkol T; Molas M; Hanson R W
Department of Biochemistry, Case Western Reserve University, School of Medicine, Cleveland, Ohio 44106-4935.
European journal of biochemistry / FEBS (GERMANY) Dec 1 1994, 226 (2) p255-66, ISSN 0014-2956 Journal Code: 0107600
Contract/Grant No.: DK-21859; DK; NIDDK
Document type: Journal Article; Review; Review, Tutorial
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

An evaluation of receptor-mediated gene transfer using synthetic *DNA*-*ligand* complexes.
... animals. Genes introduced by this technique have been shown to be expressed in the target tissue for varying periods. However, to be useful for gene *therapy* , it is critical that both the chemical properties and physical interactions of the reagents involved in the design of the DNA delivery vehicle be rigorously characterized. In this *review*, we discuss the critical steps in the preparation of the *DNA*-*ligand* complex and the factors involved in the delivery and regulated expression of a transgene in animal tissues. The feasibility of using this technique for the...

13/3,K/2 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2002 Elsevier Science B.V. All rts. reserv.

11553308 EMBASE No: 2002125069
Tracing transgene expression in cancer gene *therapy*: A requirement for rational progress in the field
Sangro B.; Qian C.; Ruiz J.; Prieto J.
Dr. B. Sangro, Department of Internal Medicine, University Clinic, University of Navarra, 31080 Pamplona Spain
AUTHOR EMAIL: bsangro@unav.es
Molecular Imaging and Biology (MOL. IMAGING BIOL.) (United States) 2002, 4/1 (27-33)
CODEN: CPIMF ISSN: 1536-1632
PUBLISHER ITEM IDENTIFIER: S1095039700000455
DOCUMENT TYPE: Journal ; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 44

Tracing transgene expression in cancer gene *therapy*: A requirement for rational progress in the field

This *review* summarizes the status of gene *therapy* in medicine and the role of molecular imaging in its development. In gene *therapy*, genetic material is introduced into cells in order to generate a specific biological effect. Natural (viruses) or artificial molecular constructs, named gene *therapy* vectors, are used to achieve efficient cell transduction. This new form of *therapy* can be used for treating a broad variety of conditions including hereditary diseases, infections,

degenerative disorders and cancer. Monitoring transgene expression using non-invasive imaging techniques is a necessary complement for the development of clinical gene *therapy*. Recent developments in magnetic resonance imaging afford the possibility of detecting gene transfer in vivo, but the most promising results have been obtained with positron emission tomography (PET). PET allows imaging gene *therapy* products by administration of a labeled substrate when the transgene codes for an enzyme or by administration of a labeled ligand when the transgene codes...

...or dopamine receptors) is used to detect the selective trapping of its radiolabeled ligand in the transduced cells. One of the approaches for the genetic *treatment* of cancer consists in transferring the "suicide genes" into tumor cells, the most common being the thymidine kinase (tk) of herpes viruses. Different nucleoside analogs...

...extremely encouraging. Reliable methods for the in vivo tracing of transgene expression in humans have to be developed in order for the field of gene *therapy* to mature. PET has emerged as a powerful tool to assist in achieving this goal. (c) 2001 Elsevier Science, Inc. All rights reserved.
DRUG DESCRIPTORS:
gene product--drug development--dv; gene product--drug *therapy*--dt; *DNA* ; *ligand*; enzyme--endogenous compound--ec; receptor--endogenous compound --ec; somatostatin receptor--endogenous compound--ec; dopamine receptor --endogenous compound--ec; thymidine kinase--drug *therapy*--dt; nucleoside analog--drug *therapy*--dt; liposome
MEDICAL DESCRIPTORS:
*gene *therapy*; *cancer--drug *therapy*--dt
transgene; gene expression; imaging system; gene construct; virus vector; DNA vector; genetic transduction; genetic disorder--drug *therapy*--dt; infection--drug *therapy*--dt; degenerative disease--drug *therapy*--dt; gene expression profiling; non invasive measurement; nuclear magnetic resonance imaging; gene transfer; in vivo study; positron emission tomography; genetic code; isotope labeling; suicide gene...

13/3,K/3 (Item 2 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2002 Elsevier Science B.V. All rts. reserv.

06429005 EMBASE No: 1996078493
Noninfectious gene transfer and expression systems for cancer gene *therapy*
Cooper M.J.
BioMedical Research Building 3 West, Case Western Reserve University, School of Medicine, 10900 Euclid Ave,Cleveland, OH 44106-4937 United States
Seminars in Oncology (SEMIN. ONCOL.) (United States) 1996, 23/1 (172-187)
CODEN: SOLGA ISSN: 0093-7754
DOCUMENT TYPE: Journal; Review
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

Noninfectious gene transfer and expression systems for cancer gene *therapy*

Gene *therapy* provides a significant opportunity to devise novel strategies for the control or cure of cancer. Success of this modality will ultimately depend on the ability to express a therapeutic gene of interest at high levels, and specific gene delivery to targeted tumor cells will minimize toxicities. Although current gene *therapy* trials typically use viral-based, infectious vectors to express suitable target genes in human cancer cells, these vectors have significant limitations in their expression characteristics...
DRUG DESCRIPTORS:
calcium phosphate; cancer vaccine--drug development--dv; *dna*; *ligand*;

liposome; polylysine
MEDICAL DESCRIPTORS:
*cancer--*therapy*--th
clinical article; episome; expression vector; gene targeting; gene *therapy*; gene transfer; genetic transfection; human; intradermal drug administration; intramuscular drug administration; intraperitoneal drug administration; intratumoral drug administration; intravenous drug administration; nonhuman; plasmid; priority journal; promoter region; *review*; subcutaneous drug administration

13/3,K/4 (Item 3 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2002 Elsevier Science B.V. All rts. reserv.

05886591 EMBASE No: 1994304195
Somatic gene *therapy* for cystic fibrosis
O'Neal W.K.; Beaudet A.L.
Dept Molecular and Human Genetics, Baylor College of Medicine, One Baylor Plaza, T619,Houston, TX 77030 United States
Human Molecular Genetics (HUM. MOL. GENET.) (United Kingdom) 1994, 3/REVIEW (1497-1502)
CODEN: HMGEE ISSN: 0964-6906
DOCUMENT TYPE: Journal; Review
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

Somatic gene *therapy* for cystic fibrosis

There is considerable potential to ameliorate the pulmonary disease in cystic fibrosis (CF) using somatic gene *therapy*. Even low levels of expression of the gene in airways epithelium may be beneficial. Adenoviral vectors, DNA-liposome complexes, adeno-associated viral vectors, and *DNA*-*ligand* complexes have been used effectively in vitro and have been tested in animals to varying extent. Adenoviral vectors and DNA- liposome complexes are being used...
MEDICAL DESCRIPTORS:
*cystic fibrosis--*therapy*--th; *cystic fibrosis--congenital disorder--cn; *gene *therapy*
adenovirus; clinical trial; electrophysiology; gene targeting; human; lung disease--*therapy*--th; nonhuman; nose mucosa; priority journal; respiratory epithelium; *review*; somatic cell genetics; virus vector
?ds

Set	Items	Description
S1	718	(POLYNUCLEOTIDE OR RNA OR DNA) (W) (LIGAND)
S2	3	S1 (S) (ANTIVIRUS OR ANTIVIRAL)
S3	2	RD (unique items)
S4	0	S1 AND (VIRUS (W) (CAPSID OR ENVELOPE))
S5	4	S1 AND (GB OR GH OR GL)
S6	2	RD (unique items)
S7	2	S1 AND (VIRAL (W) INFECTION)
S8	1	RD (unique items)
S9	10	S1 AND (ANTIVIRAL OR ANTIVIRUS)
S10	7	RD (unique items)
S11	74	S1 AND (TREATMENT OR THERAPY)
S12	6	S11 AND REVIEW
S13	4	RD (unique items)

?logoff
05jun02 14:11:39 User259876 Session D354.2
$2.49 0.778 DialUnits File155
$0.84 4 Type(s) in Format 3
$0.84 4 Types
$3.33 Estimated cost File155
$3.90 0.696 DialUnits File5
$10.50 6 Type(s) in Format 3
$10.50 6 Types

```
$14.40  Estimated cos[redacted]File5
       $13.18    1.464 DialUnits File73
          $15.00  6 Type(s) in Format  3
       $15.00  6 Types
$28.18  Estimated cost File73
        OneSearch, 3 files,  2.939 DialUnits FileOS
 $2.16  TELNET
$48.07  Estimated cost this search
$48.43  Estimated total session cost   3.031 DialUnits


### Status: Signed Off. (10 minutes)
```

Set Name side by side	Query	Hit Count	Set Name result set
	DB=USPT,PGPB,JPAB,EPAB,DWPI,TDBD; PLUR=YES; OP=AND		
L7	L6 and (virus adj (capsid or envelope))	8	L7
L6	((polynucleotide or RNA or DNA) adj ligand) and (antiviral or antivirus)	92	L6
L5	L4 and ((polynucleotide or RNA or DNA) adj ligand)	51	L5
L4	L3 and (ligand)	838	L4
L3	L2 same (polynucleotide or RNA or DNA)	3816	L3
L2	(antiviral) or (anti-viral) or (anti adj viral)	29801	L2
L1	Liu-fenyong.in.	10	L1

END OF SEARCH HISTORY